New drugs in prostate cancer

Sangjun Yoo; Se Young Choi; Dalsan You; Choung Soo Kim

doi:10.1016/j.prnil.2016.05.001

New drugs in prostate cancer

Sangjun Yoo, Se Young Choi, Dalsan You, Choung Soo Kim

Research output: Contribution to journal › Review article › peer-review

26 Scopus citations

Abstract

The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other treatments are slim, and the need for new agents persists. In recent years, novel agents, including abiraterone, enzalutamide, cabazitaxel, radium-223, and sipuleucel-T, have been approved for the treatment of CRPC, and more such agents based on diverse mechanisms are under investigation or evaluation. In this article, the authors reviewed the current literature on recent advances in medical treatment of prostate cancer, especially CRPC. In addition, the authors elaborated on novel drugs for prostate cancer currently undergoing investigation and their mechanisms.

Original language	English
Pages (from-to)	37-42
Number of pages	6
Journal	Prostate International
Volume	4
Issue number	2
DOIs	https://doi.org/10.1016/j.prnil.2016.05.001
State	Published - Jun 2016

Keywords

Castration Resistant
Drug Therapy
Drugs
Investigational
Prostatic Neoplasm

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.prnil.2016.05.001

Cite this

@article{3736b8878d3a4a1e8ee4815dde998557,

title = "New drugs in prostate cancer",

abstract = "The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other treatments are slim, and the need for new agents persists. In recent years, novel agents, including abiraterone, enzalutamide, cabazitaxel, radium-223, and sipuleucel-T, have been approved for the treatment of CRPC, and more such agents based on diverse mechanisms are under investigation or evaluation. In this article, the authors reviewed the current literature on recent advances in medical treatment of prostate cancer, especially CRPC. In addition, the authors elaborated on novel drugs for prostate cancer currently undergoing investigation and their mechanisms.",

keywords = "Castration Resistant, Drug Therapy, Drugs, Investigational, Prostatic Neoplasm",

author = "Sangjun Yoo and Choi, {Se Young} and Dalsan You and Kim, {Choung Soo}",

note = "Publisher Copyright: {\textcopyright} 2016",

year = "2016",

month = jun,

doi = "10.1016/j.prnil.2016.05.001",

language = "English",

volume = "4",

pages = "37--42",

journal = "Prostate International",

issn = "2287-8882",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - New drugs in prostate cancer

AU - Yoo, Sangjun

AU - Choi, Se Young

AU - You, Dalsan

AU - Kim, Choung Soo

PY - 2016/6

Y1 - 2016/6

N2 - The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other treatments are slim, and the need for new agents persists. In recent years, novel agents, including abiraterone, enzalutamide, cabazitaxel, radium-223, and sipuleucel-T, have been approved for the treatment of CRPC, and more such agents based on diverse mechanisms are under investigation or evaluation. In this article, the authors reviewed the current literature on recent advances in medical treatment of prostate cancer, especially CRPC. In addition, the authors elaborated on novel drugs for prostate cancer currently undergoing investigation and their mechanisms.

AB - The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other treatments are slim, and the need for new agents persists. In recent years, novel agents, including abiraterone, enzalutamide, cabazitaxel, radium-223, and sipuleucel-T, have been approved for the treatment of CRPC, and more such agents based on diverse mechanisms are under investigation or evaluation. In this article, the authors reviewed the current literature on recent advances in medical treatment of prostate cancer, especially CRPC. In addition, the authors elaborated on novel drugs for prostate cancer currently undergoing investigation and their mechanisms.

KW - Castration Resistant

KW - Drug Therapy

KW - Drugs

KW - Investigational

KW - Prostatic Neoplasm

UR - http://www.scopus.com/inward/record.url?scp=84973160860&partnerID=8YFLogxK

U2 - 10.1016/j.prnil.2016.05.001

DO - 10.1016/j.prnil.2016.05.001

M3 - Review article

AN - SCOPUS:84973160860

SN - 2287-8882

VL - 4

SP - 37

EP - 42

JO - Prostate International

JF - Prostate International

IS - 2

ER -

New drugs in prostate cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this